Though the therapy, Kresladi, isn’t seen as a big seller, its clearance is a step forward for a company that’s lost most of ...

The buyout, which includes another $525 million in floated payouts, hands Otsuka a medicine it sees as a possibly ...

If consummated, the deal would hand Merck a treatment that could challenge Novartis’ fast-selling Scemblix. But the low ...

The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...

Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, ...

The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients ...

Xpovio combined with Incyte’s Jakafi helped on one key measure but missed on other goal in a disorder that, by one analyst’s ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...

Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when ...

The clearance, issued 54 days after an approval submission, gives Novo another chance to claw back market share from Eli ...

After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes ...